Indivior, a global specialty pharmaceutical company, announced yesterday its financial results for the first half of 2018.
The company reported net revenues of USD524m in the first half of 2018 compared with USD553m in the year-ago period.
The firm posted adjusted operating profit at USD183m in the first half of 2018 compared with USD269m in the same period in 2017.
US market growth in H1 2018 continued at low double-digit percentage levels, primarily driven by the Medicaid channel.
Shaun Thaxter, CEO of Indivior, commented, 'While our base US business has recently been impacted by known risks that have materialised, we remain committed to our vision to ensure that patients around the world have access to evidence-based treatment for their addiction and its co-occurring disorders. Our primary focus is to ensure the successful progression of SUBLOCADE as it begins its transformation of the treatment of opioid use disorder.'
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva